SLC5A2 and type 2 diabetes mellitus: According to the European Medicines Agency (EMA) as of May 2015 in EudraVigilance, a total of 101 cases of euDKA had been reported worldwide in T2DM patients treated with SGLT-2 inhibitors [4].